Evidence map›Paper›PMID 38778871›Full record

Reviewnpj women's health2024

Alzheimer's disease as a women's health challenge: a call for action on integrative precision medicine approaches.

S Miramontes, C Pereda Serras, S R Woldemariam, U Khan, Y Li, A S Tang, E Tsoy, T T Oskotsky, M Sirota

Abstract readReview
In one paragraph

Review in npj women's health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Lipid profiling reveals unsaturated lipid reduction in women with Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

S Miramontes *Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA USA.
C Pereda Serras *Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA USA.
S R WoldemariamBakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA USA.
U KhanBakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA USA.
Y LiBakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA USA.
A S TangBakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA USA.
E TsoyMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA USA.
T T OskotskyBakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA USA.
M SirotaBakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA USA.

Funding

An Integrative Multi-Omics Approach to Elucidate Sex-Specific Differences in Alzheimers DiseaseR01AG060393 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SIROTA, MARINA · 2018 to 2022
$4.1M
Pharmaceutical Sciences and PharmacogenomicsT32GM142516 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Su Guo · 2022 to 2026
$2.4M
Leveraging Clinical Data for Phenotyping and Predictive Modelling of Alzheimer’s DiseaseF30AG079504 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TANG, ALICE SUMMER · 2022 to 2025
$187k
Evaluating social and clinical risk factors for the progression from Mild CognitiveImpairment to Alzheimer’s Disease and Related Dementias using Real World ClinicalDataF31AG085938 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIZARRAGA, SILVIA MIRAMONTES · 2024 to 2025
$92k
NIA NIH HHS F30 AG079504NIA NIH HHS F31 AG085938NIA NIH HHS R01 AG060393NIGMS NIH HHS T32 GM142516
6 · The paper itself

Abstract

Alzheimer's Disease (AD) is marked by pronounced sex differences in pathophysiology and progression. However, the field has yet to fully recognize AD as a women's health issue, delaying the development of targeted preventative strategies and treatments. This perspective explores the elements impacting AD in women, identifying sex specificity in risk factors, highlighting new diagnostic approaches with electronic health records, and reviewing key molecular studies to underscore the need for integrative precision medicine approaches. Established AD risk factors such as advancing age, the apolipoprotein E4 allele, and poorer cardiovascular health affect women differently. We also shed light on sociocultural risk factors, focusing on the gender disparities that may play a role in AD development. From a biological perspective, sex differences in AD are apparent in biomarkers and transcriptomics, further emphasizing the need for targeted diagnostics and treatments. The convergence of novel multiomics data and cutting-edge computational tools provides a unique opportunity to study the molecular underpinnings behind sex dimorphism in AD. Thus, precision medicine emerges as a promising framework for understanding AD pathogenesis through the integration of genetics, sex, environment, and lifestyle. By characterizing AD as a women's health challenge, we can catalyze a transformative shift in AD research and care, marked by improved diagnostic accuracy, targeted interventions, and ultimately, enhanced clinical outcomes.

Indexed as

DiagnosisDiseasesTherapeutics

Identifiers

PMID38778871
PMCPMC11106001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.